Cyrus Mozayeni, Vedere Bio CEO

Months af­ter No­var­tis buy­out, the old Vedere Bio team is back at it with a new pipeline and a fresh $77M

What do you do when No­var­tis plunks down $150 mil­lion to buy your start­up be­fore you even hit the clin­ic? If you’re Cyrus Moza­yeni, you start a new one.

On Tues­day, Moza­yeni pulled the cur­tain on a hefty $77 mil­lion Se­ries A round to get the ball rolling at Vedere Bio II — an oc­u­lar gene ther­a­py com­pa­ny launched by the same lead­er­ship and re­search team from the first Vedere. Af­ter hand­ing their lead pro­gram to No­var­tis in 2020, Moza­yeni’s team is now re­group­ing around a dif­fer­ent pre­clin­i­cal pipeline which, like the first, is based on tech from the UC Berke­ley labs of Ehud Isacoff and John Flan­nery and UPenn.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.